Patient-derived models of brain metastases recapitulate human disseminated disease

Cell Rep Med. 2022 May 17;3(5):100623. doi: 10.1016/j.xcrm.2022.100623. Epub 2022 May 3.

Abstract

Dissemination of cancer cells from primary tumors to the brain occurs in many cancer patients, increasing morbidity and death. There is an unmet medical need to develop translational platforms to evaluate therapeutic responses. Toward this goal, we established a library of 23 patient-derived xenografts (PDXs) of brain metastases (BMs) from eight distinct primary tumors. In vivo tumor formation correlates with patients' poor survival. Mouse subcutaneous xenografts develop spontaneous metastases and intracardiac PDXs increase dissemination to the CNS, both models mimicking the dissemination pattern of the donor patient. We test the FDA-approved drugs buparlisib (pan-PI3K inhibitor) and everolimus (mTOR inhibitor) and show their efficacy in treating our models. Finally, we show by RNA sequencing that human BMs and their matched PDXs have similar transcriptional profiles. Overall, these models of BMs recapitulate the biology of human metastatic disease and can be valuable translational platforms for precision medicine.

Keywords: PI3K inhibitor; RNA sequencing; brain metastases; mTOR inhibitor; patient-derived cultures; patient-derived xenografts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Neoplasms* / drug therapy
  • Disease Models, Animal
  • Heterografts
  • Humans
  • Mice
  • Phosphatidylinositol 3-Kinases* / therapeutic use
  • Phosphoinositide-3 Kinase Inhibitors
  • Precision Medicine

Substances

  • Phosphoinositide-3 Kinase Inhibitors